Zhejiang Huahai Pharmaceutical

CLOSEOUT LETTER Zhejiang Huahai Pharmaceutical MARCS-CMS 566685 — November 04, 2021 More Warning Letters Warning Letters About Warning and Close-Out Letters Product: Drugs Recipient: Recipient Name Mr. Baohua Chen Recipient Title Chairman and President Zhejiang Huahai Pharmaceutical Xunqiao Xin Street Linhai Shi Taizhou Shi Zhejiang Sheng , 317024 China Issuing Office: Center for Drug Evaluation and Research | CDER United States Dear Mr. Chen: The Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our Warning Letter 320-19-04 dated November 29, 2018. Based on our evaluation, it appears that you have addressed the deviations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections. This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The FDA expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should deviations be observed during a subsequent inspection or through other means. Sincerely, /S/ Rory K. Geyer Compliance Officer Division of Drug Quality II Office of Manufacturing Quality Office of Compliance Center for Drug Evaluation and Research FDA Content current as of: 11/10/2021 Regulated Product(s) Drugs